Verici DX
VRCI · AIM · Health Care · mcap £5.1m · 0.2p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 09 Oct 26 | Routine | Posting of Circular & Notice of GM | |
| 09 Oct 26 | Offer | WRAP Retail Offer for up to £250,000
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces a retail offer via the Winterflood Retail Access Platform (“WRAP”) to raise up to £250,000 (the “Retail Offer”) thro |
|
| 09 Oct 26 | Fundraise | Result of Placing
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, is pleased to announce that, further to the announcement made at 5.00pm on 8 October 2026 regarding the Placing (the “Launch A |
|
| 09 Oct 26 | Close of Accelerated Bookbuild
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, is pleased to announce that, further to the announcement made at 5.00pm on 8 October 2026 (the “Launch Announcement”), the Pla |
||
| 08 Oct 26 | Fundraise | Launch of Proposed Placing
Launch of Proposed Placing of 4,000,000,000 New Ordinary Shares at a price of 0.2 pence per share |
+0.0% |
| 01 Oct 26 | Capital Access Window - Verici Dx PLC | +0.0% | |
| 30 Sep 26 | Results | Half-year Results
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces its unaudited interim results for the six months ended 30 June 2026 (“H1 2026”). |
+7.1% |
| 30 Sep 26 | Fundraise | Proposed Fundraise and Capital Access Window
UPON PUBLICATION OF THIS ANNOUNCEMENT, THE INSIDE INFORMATION CONTAINED HEREIN IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. |
+7.1% |
| 21 Sep 26 | Q4 launch of TranscripTx™ genetic test
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it will be launching TranscripTx™, a first-in-class genetic test specifically designed for the transplant community |
+0.0% | |
| 18 Sep 26 | Holding | Holding(s) in Company | |
| 27 Aug 26 | Holding | Holding(s) in Company | |
| 11 Aug 26 | Certified Service Provider agreement with Olink®
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has achieved status as an Olink Certified Service Provider, part of Thermo Fisher's Life Sciences Solutions. |
+11.1% | |
| 04 Aug 26 | Holding | Holding(s) in Company | |
| 28 Jul 26 | Routine | Result of AGM | |
| 06 Jul 26 | Investor presentation
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, will provide a live online presentation relating to the Company's final results announced on 29 June 2026, and recent fundrais |
+0.0% | |
| 01 Jul 26 | Holding | Holding(s) in Company | |
| 29 Jun 26 | Results | Final Results
Final results for the year ended 31 December 2025 |
+0.0% |
| 25 Jun 26 | Holding | Holding(s) in Company | |
| 24 Jun 26 | Holding | Holding(s) in Company | |
| 24 Jun 26 | Holding | Holding(s) in Company | |
| 24 Jun 26 | Holding | Holding(s) in Company | |
| 24 Jun 26 | Holding | Holding(s) in Company | |
| 24 Jun 26 | Holding | Holding(s) in Company | |
| 24 Jun 26 | New York State clinical lab certification received
Nationwide access to Tutivia™ extended with authorisation to all 50 US states completed |
+0.0% | |
| 23 Jun 26 | Holding | Holding(s) in Company | |
| 22 Jun 26 | Routine | Result of General Meeting | |
| 19 Jun 26 | Holding | Holding(s) in Company | |
| 12 Jun 26 | Fundraise | Result of WRAP Retail Offer
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, confirms, further to the announcements made on 8 June 2026, the result of its WRAP Retail Offer at the Issue Price of 0.35 pe |
+0.0% |
| 08 Jun 26 | Routine | Publication of Circular & Notice of GM | |
| 08 Jun 26 | Offer | WRAP Retail Offer for up to £200,000
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, is pleased to announce a retail offer via the Winterflood Retail Access Platform ("WRAP") to raise up to £200,000 (the "WRAP |
+6.7% |
| 05 Jun 26 | Fundraise | Result of Placing & raising gross proceeds c£2.5m
IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED |
−11.8% |
| 05 Jun 26 | Fundraise | Proposed Fundraising via Placing
IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED |
−11.8% |
| 04 Jun 26 | Holding | Holding(s) in Company | |
| 02 Jun 26 | Holding | Holding(s) in Company | |
| 02 Jun 26 | Study validating economic advantages of PTRA test
Study validating economic advantages of PTRA test published |
+0.0% | |
| 02 Jun 26 | AMA grants additional CPT® Code for ProtegaTM
American Medical Association grants Verici Dx additional CPT® Code for ProtegaTM |
+0.0% | |
| 27 May 26 | Holding | Holding(s) in Company | |
| 22 May 26 | Holding | Holding(s) in Company | |
| 19 May 26 | Clinical study validating PTRA test published
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces the publication of a peer-reviewed clinical validation study of its Pre-Transplant Rejection Assessment ("PTRA") te |
+0.0% | |
| 13 May 26 | Holding | Holding(s) in Company | |
| 11 May 26 | Holding | Holding(s) in Company | |
| 11 May 26 | Holding | Holding(s) in Company | |
| 30 Apr 26 | Holding | Holding(s) in Company | |
| 24 Apr 26 | Holding | Holding(s) in Company | |
| 16 Apr 26 | Trading update | Positive Q1 Trading Update
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, provides a trading update demonstrating strong momentum for the three months ended 31 March 2026 (Q1 '26). |
+9.5% |
| 10 Apr 26 | Holding | Holding(s) in Company | |
| 07 Apr 26 | Holding | Holding(s) in Company | |
| 31 Mar 26 | Board change | Directorate Change
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that James McCullough, Non-Executive Director, has resigned from the Board with immediate effect to focus on his ro |
+0.0% |
| 30 Mar 26 | Holding | Holding(s) in Company | |
| 05 Feb 26 | Trading update | FY25 Trading Update
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, provides a trading update for the year ended 31 December 2025 ("FY25"), a year of strong growth and commercial progress for t |
+0.0% |
| 05 Feb 26 | Agreement with BCBS of Illinois for Tutivia™
Agreement with Blue Cross and Blue Shield of Illinois for Tutivia™ |
+0.0% | |
| 12 Nov 25 | Completion of CAP accreditation audit
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has successfully completed its second biennial inspection of the Company's clinical laboratory, accredited |
+2.3% | |
| 06 Nov 25 | Provider Participation Agreement with Prime Health
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has signed a Provider Participation Agreement ('the Agreement') with Prime Health Services ('Prime Health') |
+16.0% | |
| 03 Nov 25 | Completion of ISO 27001 surveillance audit
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has successfully completed the annual surveillance audit for its ISO 27001:2022 certification. |
−3.6% | |
| 30 Oct 25 | Options revision & Grant of new share options
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that upon the recommendation of the Company's Remuneration Committee, it has repriced certain existing options over |
−3.4% | |
| 06 Oct 25 | Board change | Directorate Change
Verici Dx plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces the appointment to the Board of Aubrey Powell, as Non-executive Director, with immediate effect. |
+11.5% |
| 06 Oct 25 | Update on Tutivia™ test adoption
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces positive progress in its plans to drive strong Tutivia™ sales growth following the equity fundraise completed in Ju |
+11.5% |
Company filings. Not investment advice.